Fact-Finding Survey of Information Provision and Medication Instruction on Idarucizumab for Pharmacists
- VernacularTitle:薬剤師におけるイダルシズマブの認知度および情報提供・指導の実態調査
- Author:
Kanako NAKAHARA
1
;
Ikkou HIRATA
2
;
Toru TERAGUCHI
2
;
Ryohkan FUNAKOSHI
2
Author Information
- Keywords: risk management plan; dabigatran etexilate methanesulfonate; idarucizumab; antagonist; direct oral anticoagulant
- From:Japanese Journal of Drug Informatics 2023;25(2):61-66
- CountryJapan
- Language:Japanese
- Abstract: Objective: Providing patients with information and medication instruction regarding direct oral anticoagulant (DOAC)antagonists is becoming increasingly important. Comprehensive knowledge of DOAC antagonists can expedite the transportation and treatment of emergency cases, such as bleeding with antagonists, in hospitals. We investigated the awareness of idarucizumab and whether the information provided in the Risk Management Plan was reflected in the actual provision of information and medication instruction.Methods: Pharmacists in dispensing pharmacies and Kameda Medical Center were included in the survey conducted from May 2022 to June 2022. Using a web-based questionnaire, we obtained answers to questions related to idarucizumab awareness. Respondents answered a series of questions regarding idarucizumab awareness, sources of information, patient information, and medication instruction.Results: We received responses from 1,118 people. In all, 25.9% pharmacists were aware of idarucizumab, and 10.3% provided information and medication instruction on DOAC antagonists to patients. Pharmaceutical companies, books, drug information departments, workshops, and wholesalers were the sources of information on idarucizumab for 24.8, 21.0, 19.0, 10.7, and 3.1% of the pharmacists, respectively.Conclusion: Pharmacists had knowledge of DOAC antagonists and provided information and instructions to patients infrequently. Improved awareness will lead to prompt response during the occurrence of adverse events such as bleeding.
